Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 237

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma

Open access
Abou-Alfa, G.K., Qin, S., Ryoo, B.-Y., Lu, S.-N., Yen, C.-J., Feng, Y.-H., Lim, H.Y., Izzo, F., Colombo, M., Sarker, D., Bolondi, L., Vaccaro, G., Harris, W.P., Chen, Z., Hubner, R.A., Meyer, T., Sun, W., Harding, J.J., Hollywood, E.M., Ma, J., Wan, P.J., Ly, M., Bomalaski, J., Johnston, A., Lin, C.-C., Chao, Y., Chen, L.-T.·2018·Annals of Oncology

Abstract

Background: Arginine depletion is a putative target in hepatocellular carcinoma (HCC). HCC often lacks argininosuccinate synthetase, a citrulline to arginine-repleting enzyme. ADI-PEG 20 is a cloned arginine degrading enzyme-arginine deiminase-conjugated with polyethylene glycol. The goal of this study was to evaluate this agent as a potential novel therapeutic for HCC after first line systemic therapy. Methods and patients: Patients with histologically proven advanced HCC and Child-Pugh up to B7 with prior systemic therapy, were randomized 2 : 1 to ADI-PEG 20 18 mg/m2 versus placebo intramuscular injection weekly. The primary end point was overall survival (OS), with 93% power to detect a 4-5.6 months increase in median OS (one-sided α = 0.025). Secondary end points included progression-free survival, safety, and arginine correlatives. Results: A total of 635 patients were enrolled: median age 61, 82% male, 60% Asian, 52% hepatitis B, 26% hepatitis C, 76% stage IV, 91% Child-Pugh A, 70% progressed on sorafenib and 16% were intolerant. Median OS was 7.8 months for ADI-PEG 20 versus 7.4 for placebo (P = 0.88, HR = 1.02) and median progression-free survival 2.6 months versus 2.6 (P = 0.07, HR = 1.17). Grade 3 fatigue and decreased appetite occurred in <5% of patients. Two patients on ADI-PEG 20 had ≥grade 3 anaphylactic reaction. Death rate within 30 days of end of treatment was 15.2% on ADI-PEG 20 versus 10.4% on placebo, none related to therapy. Post hoc analyses of arginine assessment at 4, 8, 12 and 16 weeks, demonstrated a trend of improved OS for those with more prolonged arginine depletion. Conclusion: ADI-PEG 20 monotherapy did not demonstrate an OS benefit in second line setting for HCC. It was well tolerated. Strategies to enhance prolonged arginine depletion and synergize the effect of ADI-PEG 20 are underway. Clinical Trial number: www.clinicaltrials.gov (NCT 01287585).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdy101

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 237

Metadata

Authors
Abou-Alfa, G. K., Qin, S., Ryoo, B.-Y., Lu, S.-N., Yen, C.-J., Feng, Y.-H., Lim, H. Y., Izzo, F., Colombo, M., Sarker, D., Bolondi, L., Vaccaro, G., Harris, W. P., Chen, Z., Hubner, R. A., Meyer, T., Sun, W., Harding, J. J., Hollywood, E. M., Ma, J., Wan, P. J., Ly, M., Bomalaski, J., Johnston, A., Lin, C.-C., Chao, Y., & Chen, L.-T.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2018-06
Volume
29
Issue
6
Pages
1402-1408
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2808082897
Cited by
237
References
7
FWCI
18.00
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. https://app.cochat.ai/papers/10.1093/annonc/mdy101
The paper
Abou-Alfa, G. K., Qin, S., Ryoo, B.-Y., Lu, S.-N., Yen, C.-J., Feng, Y.-H., Lim, H. Y., Izzo, F., Colombo, M., Sarker, D., Bolondi, L., Vaccaro, G., Harris, W. P., Chen, Z., Hubner, R. A., Meyer, T., Sun, W., Harding, J. J., Hollywood, E. M., . . . Chen, L.-T. (2018). Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. Annals of Oncology. https://doi.org/10.1093/annonc/mdy101

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.